Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

Oncology Financial Navigation Trial Targets Financial Toxicity Across Multiple Sites

A multisite oncology financial navigation trial examines whether structured support can lessen financial toxicity for patients facing cancer care costs.

By Dr. Revathy Mohan V.R., MBBS · Oct 21, 2026 · 4 min read

Oncology·JCO

Quality Indicators in Oncology Care Improve Outcomes Across Health Systems

Cross-sectional review finds oncology quality indicators are linked to earlier diagnosis, better adherence, improved survival, and higher patient…

Oct 21, 2026

Oncology·JCO

Pancreatic Cancer Incidence Disparities Shift in U.S. Survival Trends

A JCO analysis examines U.S. pancreatic cancer incidence disparities and survival trends from 1999 to 2021, pointing to…

Oct 21, 2026

Oncology·NLM Alerts

Targeted protein degradation expands cancer immunotherapy beyond undruggable targets

A Frontiers review explains how targeted protein degradation could reverse immune evasion, overcome resistance, and broaden cancer immunotherapy…

Oct 21, 2026

Oncology·Nature

EGFR-targeted antibody-toxin conjugate extends survival in recurrent glioma

A phase 1 glioma trial found D2C7-ATC was tolerable and linked to longer survival in a subset of…

Oct 21, 2026

Oncology·Modern HC

Tele-Oncology After COVID-19: Access Gains, Digital Gaps and Liability Risks

Tele-oncology is now embedded in cancer care, improving access and continuity while exposing digital disparities, diagnostic limits and…

Oct 21, 2026

Oncology·medRxiv

Belzutifan DFS Benefit in Adjuvant Kidney Cancer May Fade After Treatment Ends

Reconstructed trial data suggest belzutifan’s adjuvant DFS advantage in renal cell carcinoma is strongest before month 12 and…

Oct 21, 2026

Oncology·ClinicalTrials

BA1203 phase 1 trial opens in advanced solid tumors

A first-in-human phase 1 study will test BA1203 in advanced solid tumors, with safety, pharmacokinetics, and early efficacy…

Oct 21, 2026

Oncology·CID

OPTIMA AI Workshop Examines Multimodal Analysis in Breast and Lung Cancer

OPTIMA workshop findings point to multimodal AI analysis as a path to better subtype detection, treatment selection, and…

Oct 21, 2026

Oncology·Sci Transl Med

PINK1 Mitophagy May Drive Lung Cancer and Weaken KRAS Therapy

PINK1-mediated mitophagy appears to support lung cancer initiation and blunt KRAS-targeted therapy, raising a new metabolic resistance axis.

Oct 21, 2026

Oncology

Therapeutics, diagnostics and evidence shaping cancer care.

In Brief The 5-minute rounds

New hypertension guideline lowers the treatment threshold to 130/80 mm Hg.
Phase 3 GLP-1 trial reports a 20% cut in major adverse cardiac events.
FDA clears a next-generation CAR-T therapy for relapsed lymphoma.
Meta-analysis links early mobilisation to shorter ICU length of stay.
Rapid guidance broadens empiric antibiotics for suspected sepsis.